Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated

On Monday, Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro.

Activist investor Starboard Value has invested approximately $1 billion in Pfizer as the pharmaceutical giant grapples with a downturn in demand for COVID-19 vaccines and treatments.

In another positive development, Pfizer won a bid in a London court to invalidate two of GSK Plc’s (NYSE:GSK) patents relating to its respiratory syncytial virus (RSV) vaccine.

Also Read: UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract.

Pfizer and GSK are competing to tap into the respiratory syncytial virus (RSV) vaccine market, which could exceed $10 billion by 2030.

In August 2023, GSK sued Pfizer ...

Full story available on Benzinga.com